Compare Amphastar Pharmaceuticals Inc (AMPH) vs Hormel Foods Corp (HRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Hormel Foods Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Hormel Foods Corp trades at $24.54 (market cap $13.59B). The key difference: Hormel Foods Corp is far larger — about 15.7× Amphastar Pharmaceuticals Inc's market cap, and Hormel Foods Corp pays a 4.74% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | HRL | |
|---|---|---|
Market Cap | $863.95M | $13.59B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $29.25 |
52-Week Low | $16.87 | $19.74 |
Enterprise Value | $1.26B | $15.59B |
Dividend Yield | — | 4.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Hormel Foods (HRL) trades at $25.02, down 0.32% on the day, with a neutral technical signal and bearish moving averages. The company shows mixed fundamentals with a P/E of 29.44 and net income margin of 3.82%, though it has beaten earnings estimates for three consecutive quarters. Recent developments include the appointment of John Ghingo as CEO and the sale of its Brazilian CERATTI business, signaling strategic focus.
Outlook remains cautious with analyst consensus at Hold and a $26.33 price target. Key opportunities include defensive dividend income and operational improvements, while risks involve margin pressure and consumer spending challenges. The stock offers steady income but faces growth headwinds in the current environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →
